A diffuse subtype of classical Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding Hodgkin's lymphoma, lymphocytic depletion is primarily due to its rarity, which affects fewer than 1,000 people in the United States annually. This scarcity has resulted in a lack of systematic clinical studies and comprehensive data collection. Furthermore, the absence of identified genetic factors and established phenotypes complicates the characterization of this condition, making it difficult for healthcare providers to offer tailored management strategies.
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Currently, brentuximab vedotin is the only FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic depletion. Additionally, there is one active clinical trial that may provide further insights into treatment options and management strategies. For more information, you can search for ongoing studies at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic%20depletion.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic depletion
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, lymphocytic depletion is primarily due to its rarity, which affects fewer than 1,000 people in the United States annually. This scarcity has resulted in a lack of systematic clinical studies and comprehensive data collection. Furthermore, the absence of identified genetic factors and established phenotypes complicates the characterization of this condition, making it difficult for healthcare providers to offer tailored management strategies.
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Currently, brentuximab vedotin is the only FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic depletion. Additionally, there is one active clinical trial that may provide further insights into treatment options and management strategies. For more information, you can search for ongoing studies at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic%20depletion.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic depletion
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, lymphocytic depletion is primarily due to its rarity, which affects fewer than 1,000 people in the United States annually. This scarcity has resulted in a lack of systematic clinical studies and comprehensive data collection. Furthermore, the absence of identified genetic factors and established phenotypes complicates the characterization of this condition, making it difficult for healthcare providers to offer tailored management strategies.
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Currently, brentuximab vedotin is the only FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic depletion. Additionally, there is one active clinical trial that may provide further insights into treatment options and management strategies. For more information, you can search for ongoing studies at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic%20depletion.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic depletion
To navigate your care effectively, seek out an oncologist who specializes in lymphomas, particularly those with experience in rare subtypes like lymphocytic depletion. While there are currently no patient organizations specifically for this condition, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support. Participation in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare disease. Consider exploring the possibility of joining a patient registry if available in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 7 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.